Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70896 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Dhir Gala und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Liver Cirrhosis, Platelet Aggregation Inhibitors, Coronary Artery Disease. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Coronary artery disease (CAD) is common in cirrhosis patients because of shared risk factors, including metabolic syndrome and alcohol use; however, outcomes after percutaneous coronary intervention (PCI) remain poorly defined.
Aims
To evaluate outcomes after PCI in patients with cirrhosis.
Methods
We conducted a retrospective cohort study using TriNetX US Collaborative Network data from 2015 to 2024. Adults undergoing PCI were stratified by cirrhosis status, with outcomes including gastrointestinal bleeding, ischaemic events, and all‐cause mortality. Within the cirrhosis cohort, we evaluated effect modification by aetiology, disease severity, and antiplatelet strategy at 30 days after PCI. One‐to‐one propensity score matching adjusted for demographics and comorbidities, with results reported as relative risks and 95% confidence intervals.
Results
Among 3351 patients with cirrhosis undergoing PCI matched 1:1 to controls, cirrhosis was associated with higher 1‐year gastrointestinal bleeding (16.14% vs. 8.12%; p < 0.0001) and mortality (13.97% vs. 10.41%; p < 0.0001). Decompensated cirrhosis had higher gastrointestinal bleeding and mortality than compensated disease, while alcohol‐associated cirrhosis had higher gastrointestinal bleeding than metabolic dysfunction‐associated steatotic liver disease (MASLD) cirrhosis. In a 30‐day landmark analysis, antiplatelet monotherapy (aspirin or P2Y12 inhibitors) had lower 1‐year gastrointestinal bleeding (10.31% vs. 20.77%; p < 0.0001) and mortality (9.46% vs. 12.89%; p = 0.04) without increased stent restenosis compared with dual antiplatelet therapy (DAPT).
Conclusion
Cirrhosis confers substantially higher bleeding and mortality after PCI, particularly in decompensated disease. Antiplatelet monotherapy after 30 days was associated with less bleeding and improved survival, supporting abbreviated DAPT in this high‐risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Divison of Cardiology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Division of Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
- Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
- Division of Gastroenterology and Hepatology, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Sameer Rao, Manas Gunani, Anand V Kulkarni, Daniel Q Huang, Pojsakorn Danpanichkul, Ahmed Al-Khazraji, Paul Gaglio
Zitieren
APA
Gala, D., Rao, S., Gunani, M., Shah, K., Kulkarni, A. V., Wijarnpreecha, K., Huang, D. Q., Danpanichkul, P., Al-Khazraji, A., Hajifathalian, K., Lingiah, V., Gaglio, P., Duong, N., & Gerula, C. (2026). Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70896
Vancouver
Gala D, Rao S, Gunani M, Shah K, Kulkarni AV, Wijarnpreecha K, et al. Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70896
BibTeX
@article{Gala2026,
author = {Gala, Dhir and Rao, Sameer and Gunani, Manas and Shah, Kajol and Kulkarni, Anand V and Wijarnpreecha, Karn and Huang, Daniel Q and Danpanichkul, Pojsakorn and Al-Khazraji, Ahmed and Hajifathalian, Kaveh and Lingiah, Vivek and Gaglio, Paul and Duong, Nikki and Gerula, Christine},
title = {Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70896}
}
EUVIMED